Takayuki Yoshino

Kashiwa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 585 publications

PROSPER: a phase III trial of lecithinized superoxide dismutase to prevent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

PROSPER: a phase III trial of lecithinized superoxide dismutase to prevent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

Journal: ESMO gastrointestinal oncology

Published: August 12, 2026

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

Journal: JAMA oncology

Published: July 03, 2026

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

Journal: JCO precision oncology

Published: July 01, 2026

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Journal: JCO precision oncology

Published: July 01, 2026

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC.

Journal: International journal of clinical oncology

Published: June 14, 2026

Recommendations for generating real-world evidence with regulatory-grade relevance and reliability.

Recommendations for generating real-world evidence with regulatory-grade relevance and reliability.

Journal: International journal of clinical oncology

Published: June 09, 2026

Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis.

Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: June 01, 2026

Clinical utility of diagnosing lynch syndrome in gynecologic oncology: a joint statement from four japanese academic societies.

Clinical utility of diagnosing lynch syndrome in gynecologic oncology: a joint statement from four japanese academic societies.

Journal: International journal of clinical oncology

Published: May 11, 2026

Clinical utility and cost-effectiveness of universal tumor screening to identify Lynch syndrome in patients with stage II/III colorectal cancer: a prospective observational study in Japan.

Clinical utility and cost-effectiveness of universal tumor screening to identify Lynch syndrome in patients with stage II/III colorectal cancer: a prospective observational study in Japan.

Journal: International journal of clinical oncology

Published: May 10, 2026

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database.

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database.

Journal: Journal of the National Cancer Institute

Published: April 28, 2026

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 23, 2026

The Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncology.

The Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncology.

Journal: Nature medicine

Published: April 21, 2026

Showing 1-12 of 585

Last Updated: 09/26/2026